Editas Medicine,Inc. (NASDAQ:EDIT) Files An 8-K Financial Statements and Exhibits
Item9.01. Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Cpf1 License Agreement, by and between the Company and |
|
99.2 |
Amended and Restated Cas9I License Agreement, by and |
|
99.3 |
Cas9II License Agreement, by and between the Company and |
|
99.4 |
Second Amendment to Exclusive Patent License Agreement, |
Confidential treatment requested as to certain portions, which
portions have been omitted and filed separately with the
Securities and Exchange Commission.
2
About Editas Medicine, Inc. (NASDAQ:EDIT)
Editas Medicine, Inc., formerly Gengine, Inc., is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology. CRISPR/Cas9 uses a protein ribonucleic acid (RNA) complex consisting of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence that requires repair. The Company has initiated a range of research programs across multiple therapeutic areas. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs, including Non-malignant Hematologic Diseases, Duchenne Muscular Dystrophy, Cystic Fibrosis and Alpha-1 Antitrypsin Deficiency. Editas Medicine, Inc. (NASDAQ:EDIT) Recent Trading Information
Editas Medicine, Inc. (NASDAQ:EDIT) closed its last trading session up +0.18 at 18.24 with 405,557 shares trading hands.
